About Us

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), which is developing an innovative “first in-class” treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

A world-class board of directors

Discover our Board of Directors

A team of 20 people

A team focused to development

A network of worldwide experts & partners

To ensure the development of Acticor Biotech


Our drug candidate: glenzocimab

Acticor Biotech’s drug candidate, glenzocimab, is a humanized monoclonal antibody fragment (Fab), directed against the human platelet glycoprotein GPVI. GPVI blockade has demonstrated its effective antithrombotic potential in experimental models of thrombosis, without increasing pathological bleeding1.

Key features of glenzocimab relevant to a safe treatment of the acute phase of ischemic stroke are:
- Anti-thrombotic properties without additional bleeding risk, which represents the most common safety risk when using treatments that target platelets.
- Its mode of action and administration which allow to cover the acute phase of stroke.

Our product
One-product de-risked pipeline


By the end of June 2021, Acticor Biotech finalized the patients’ recruitment of the phase 1b/2a clinical trial to assess the safety of glenzocimab in Acute Ischemic Stroke as an add-on therapy to Standard of Care (ACTIMIS NCT03803007). The positive results of this study were announced on February 22, 2022. (Click here for the press release and the webinar presenting the results).

Acticor Biotech is launching an international phase 2/3 adaptive clinical trial (ACTISAVE NCT05070260) to evaluate the efficacy and safety of glenzocimab as an add-on therapy to thrombolysis, with or without additional mechanical thrombectomy, during the acute phase of Ischemic Stroke.

In 2020, in response to the global COVID-19 pandemic, Acticor Biotech proposed the use of glenzocimab to treat acute respiratory distress syndrome (ARDS) in SARS-Cov-2 infected patients, in the context of a phase 2 clinical study (GARDEN NCT04659109).The results of this study were announced on February 2, 2022. (Click here for the press release).

OUr pipeline


[1] Jiang, P. & Jandrot-Perrus, M. New advances in treating thrombotic diseases: GPVI as a platelet drug target. Drug Discov. Today 19, 1471–1475 (2014).